chlorambucil has been researched along with Fatigue in 6 studies
Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
Excerpt | Relevance | Reference |
---|---|---|
"Treatment with clarithromycin, ethambutol and rifabutin resulted in improvement of anaemia and general health as well as in regression of lymphadenopathy and splenomegaly." | 1.31 | Mycobacterium genavense infection in a patient with long-standing chronic lymphocytic leukaemia. ( Bodmer, T; Krebs, T; Lämmle, B; Zimmerli, S, 2000) |
"Bleeding tendency was seen in 17%, infections in 17%, hyperviscosity syndrome in 12%, and cardiac failure in 25% of the patients." | 1.31 | Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit. ( Angelopoulou, MK; Boussiotis, V; Dimopoulou, MN; Fessas, P; Gribabis, A; Kittas, C; Konstantopoulos, K; Kontopidou, FN; Kyrtsonis, MC; Pangalis, GA; Siakantaris, P; Vaiopoulos, GA; Vassilakopoulos, TP, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (16.67) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (33.33) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Holtzer-Goor, KM | 1 |
Schaafsma, MR | 1 |
Joosten, P | 1 |
Posthuma, EF | 1 |
Wittebol, S | 1 |
Huijgens, PC | 1 |
Mattijssen, EJ | 1 |
Vreugdenhil, G | 1 |
Visser, H | 1 |
Peters, WG | 1 |
Erjavec, Z | 1 |
Wijermans, PW | 1 |
Daenen, SM | 1 |
van der Hem, KG | 1 |
van Oers, MH | 1 |
Uyl-de Groot, CA | 1 |
Burger, JA | 1 |
Tedeschi, A | 1 |
Barr, PM | 1 |
Robak, T | 1 |
Owen, C | 1 |
Ghia, P | 1 |
Bairey, O | 1 |
Hillmen, P | 1 |
Bartlett, NL | 1 |
Li, J | 1 |
Simpson, D | 1 |
Grosicki, S | 1 |
Devereux, S | 1 |
McCarthy, H | 1 |
Coutre, S | 1 |
Quach, H | 1 |
Gaidano, G | 1 |
Maslyak, Z | 1 |
Stevens, DA | 1 |
Janssens, A | 1 |
Offner, F | 1 |
Mayer, J | 1 |
O'Dwyer, M | 1 |
Hellmann, A | 1 |
Schuh, A | 1 |
Siddiqi, T | 1 |
Polliack, A | 1 |
Tam, CS | 1 |
Suri, D | 1 |
Cheng, M | 1 |
Clow, F | 1 |
Styles, L | 1 |
James, DF | 1 |
Kipps, TJ | 1 |
Else, M | 1 |
Cocks, K | 1 |
Crofts, S | 1 |
Wade, R | 1 |
Richards, SM | 1 |
Catovsky, D | 1 |
Smith, AG | 1 |
Krebs, T | 1 |
Zimmerli, S | 1 |
Bodmer, T | 1 |
Lämmle, B | 1 |
Kyrtsonis, MC | 1 |
Vassilakopoulos, TP | 1 |
Angelopoulou, MK | 1 |
Siakantaris, P | 1 |
Kontopidou, FN | 1 |
Dimopoulou, MN | 1 |
Boussiotis, V | 1 |
Gribabis, A | 1 |
Konstantopoulos, K | 1 |
Vaiopoulos, GA | 1 |
Fessas, P | 1 |
Kittas, C | 1 |
Pangalis, GA | 1 |
Thorpe, P | 1 |
Hassal, J | 1 |
York, J | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2019-04-11 | Terminated (stopped due to Insufficient accrual) | ||
Long-term Effect of Chronic Ibrutinib Therapy on Left Atrial Function[NCT03751410] | 40 participants (Actual) | Observational [Patient Registry] | 2018-12-01 | Completed | |||
Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[NCT01722487] | Phase 3 | 269 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)[NCT03469895] | 40 participants (Actual) | Observational | 2017-07-21 | Active, not recruiting | |||
Phase III Randomized Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Early Stage CLL With High Risk of Early Disease Progression[NCT04178798] | Phase 3 | 22 participants (Actual) | Interventional | 2019-12-09 | Active, not recruiting | ||
Chronic Lymphocytic Leukemia Trial 4: A Randomized Comparison of Chlorambucil, Fludarabine and Fludarabine Plus Cyclophosphamide[NCT00004218] | Phase 3 | 0 participants | Interventional | 1999-10-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment
Intervention | Participants (Count of Participants) |
---|---|
Ibrutinib Plus Rituximab | 0 |
ORR is defined as the proportion of subjects who achieved complete response (CR), complete response with incomplete marrow recovery (CRi), nodule partial response (nPR) or PR per IRC assessment. Response criteria are as outlined in the International Workshop on CLL (iwCLL) 2008 criteria with the 2012 iwCLL modification stating that treatment-related lymphocytosis in the setting of improvement in other parameters was not considered as PD and the 2013 iwCLL clarification of criteria for a partial response to therapy. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | percentage of participants (Number) |
---|---|
Ibrutinib | 82.4 |
Chlorambucil | 35.3 |
OS is calculated for all randomized subjects as the duration of time from the date of randomization to the date of death due to any cause or the date last known alive for subjects who were not known to have died at study closure. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Months (Median) |
---|---|
Ibrutinib | NA |
Chlorambucil | NA |
"The primary objective of this study was to evaluate the efficacy of Ibrutinib compared with Chlorambucil based on the independent review committee (IRC) assessment of PFS~Progressive disease according to 2008 IWCLL guidelines was defined as:~Group A~Lymphadenopathy, increase ≥50%~Hepatomegaly, increase ≥50%~Splenomegaly, increase ≥50%~Blood lymphocytes, increase ≥ 50% over baseline~Group B~Platelets counts, decrease of ≥ 50% from baseline secondary to CLL~Hemoglobin, decrease of > 2 g/dL from baseline secondary to CLL" (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Months (Median) |
---|---|
Ibrutinib | NA |
Chlorambucil | 18.9 |
The proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 45.6 |
Chlorambucil | 20.3 |
In randomized subjects with baseline hemoglobin ≤ 11 g/dL, the proportion of subjects who achieved Hemoglobin >11 g/dL or increase ≥ 2 g/dL over baseline persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 84.3 |
Chlorambucil | 45.5 |
The proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline and persisted continuously for ≥56 days (8 weeks) without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with the cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 27.2 |
Chlorambucil | 11.3 |
In randomized subjects with baseline platelet ≤ 100 x 10^9/L, the proportion of subjects who achieved platelet >100 x 10^9/L or increase ≥50% over baseline persisted continuously for ≥56 days (8 wee without blood transfusion or growth factors. (NCT01722487)
Timeframe: Analysis was conducted when 15 months had elapsed after the last subject was randomized with cutoff date of 4 May 2015. The median follow-up time is 18 month.
Intervention | Percentage of Participants (Number) |
---|---|
Ibrutinib | 77.1 |
Chlorambucil | 42.9 |
3 trials available for chlorambucil and Fatigue
Article | Year |
---|---|
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
Topics: Adenine; Aged; Antineoplastic Agents; Chlorambucil; Diarrhea; Disease-Free Survival; Fatigue; Female | 2015 |
Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Chlorambuc | 2012 |
Cytotoxic therapy in rheumatoid disease.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Chlorambucil; Clinical Trials as Topic; Fatigue; Fem | 1971 |
3 other studies available for chlorambucil and Fatigue
Article | Year |
---|---|
Quality of life of patients with chronic lymphocytic leukaemia in the Netherlands: results of a longitudinal multicentre study.
Topics: Adult; Aged; Chlorambucil; Dyspnea; Fatigue; Female; Health Status; Humans; Leukemia, Lymphocytic, C | 2015 |
Mycobacterium genavense infection in a patient with long-standing chronic lymphocytic leukaemia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibiotics, Antitubercula | 2000 |
Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
Topics: Adult; Aged; Aged, 80 and over; Blood Viscosity; Cardiac Output, Low; Chlorambucil; Fatigue; Female; | 2001 |